Coherus BioSciences (NASDAQ:CHRS) specializes in developing and commercializing biosimilar therapies, aiming to increase access to important medications for patients worldwide. The company operates in a highly competitive and regulated biopharmaceutical space, focusing on oncology and immuno-oncology products among other therapeutic areas. Coherus BioSciences' project pipeline is designed to challenge the status quo in medicine, with the objective of providing more affordable and accessible treatment options. Through strategic collaborations and in-house development, the company works tirelessly to bring transformative medications to market, reflecting its commitment to improving patient care and outcomes.